Advertisement

Topics

Novartis, Medicines For Malaria Venture launch KAF156 trial in Africa

10:41 EDT 22 Aug 2017 | CentreWatch

Novartis and Medicines for Malaria Venture (MMV) have launched a patient trial for KAF156, a next-generation antimalarial compound with the potential to treat drug-resistant strains of the malaria parasite. The trial will test the efficacy of KAF156 in combination with a new, improved formulation of the existing antimalarial lumefantrine. The first trial center is operational […]

The post Novartis, Medicines For Malaria Venture launch KAF156 trial in Africa appeared first on CenterWatch News Online.

Original Article: Novartis, Medicines For Malaria Venture launch KAF156 trial in Africa

NEXT ARTICLE

More From BioPortfolio on "Novartis, Medicines For Malaria Venture launch KAF156 trial in Africa"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Infectious-diseases
Antiretroviral Therapy Clostridium Difficile Ebola HIV & AIDS Infectious Diseases Influenza Malaria Measles Sepsis Swine Flu Tropical Medicine Tuberculosis Infectious diseases are caused by pathogenic...